Immatics N.V.
NASDAQ: IMTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Harpreet Singh
- Employees
- 554
- Headquarters
- Tübingen, Germany
- IPO year
- 2018
- Market cap
- $1.3B
- Website
- https://www.immatics.com
Loading IMTX…
Loading profile data…Frequently asked questions about IMTX
What does Immatics N.V. (IMTX) do?
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT)...
Where does IMTX trade?
Immatics N.V. (IMTX) trades on the NASDAQ Capital Market.
What sector is IMTX in?
Immatics N.V. (IMTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Immatics N.V.?
Harpreet Singh is the chief executive officer of Immatics N.V. (IMTX).
Where is Immatics N.V. headquartered?
Immatics N.V. is headquartered in Germany.
Does IMTX pay a dividend?
Immatics N.V. (IMTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IMTX go public?
Immatics N.V. (IMTX) completed its initial public offering in 2018.